Metabolomics analysis and modeling suggest a lysophosphocholines-PAF receptor interaction in fibromyalgia

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Caboni, Pierluigi ^a   Liori, Barbara ^a   Kumar, Amit ^a   Santoru, Maria Laura ^a   Asthana, Shailendra ^a   Pieroni, Enrico ^b   Fais, Antonella ^a   Era, Benedetta ^a   Cacace, Enrico ^a   Ruggiero, Valeria ^a   Atzori, Luigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CENTER FOR ADVANCED STUDIES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYL SN GLYCERO 3 PHOSPHOCHOLINE RECEPTOR; 1 HEXADECANOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1 TETRADECANOYL SN GLYCERO 3 PHOSPHOCHOLINE; CERAMIDE; LYSOPHOSPHOCHOLINE; LYSOPHOSPHOLIPID; PHOSPHORYLCHOLINE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR;

ADULT; AGED; ARTICLE; BINDING SITE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; HUMAN; LIGAND BINDING; LIPIDOMICS; LIQUID CHROMATOGRAPHY; METABOLITE; METABOLOMICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN PROTEIN INTERACTION; QUADRUPOLE MASS SPECTROMETRY; STRUCTURE ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS; BIOLOGICAL MODEL; MASS SPECTROMETRY; METABOLISM; MULTIVARIATE ANALYSIS;

CHROMATOGRAPHY, LIQUID; FEMALE; FIBROMYALGIA; HUMANS; MASS SPECTROMETRY; METABOLOMICS; MODELS, BIOLOGICAL; MOLECULAR DYNAMICS SIMULATION; MULTIVARIATE ANALYSIS; PHOSPHORYLCHOLINE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84907222775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107626     Document Type: Article

References (37)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160-172.
2. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, et al (2010) The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Research 62: 600-610.
3. Altindag O, Celik H (2006) Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep 11: 131-135.
4. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, et al (2006) Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 26: 598-603.
5. Cordero MD, Alcocer-Gomez E, Cano-Garcia FJ, De Miguel M, Carrion AM, et al (2011) Clinical symptoms in fibromyalgia are better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma. PLoS One 6: e26915.
6. Oestvang J, Anthonsen MW, Johansen B (2011) LysoPC and PAF trigger arachidonic acid release by divergent signaling mechanisms in monocytes. J Lipids Article ID 532145, 11 pages; doi:10.1155/2011/532145
7. Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR (2007) An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res 6: 3456-3464.
8. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, et al. (2013) The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis & Rheumatism 5: 2015-2023.
9. Griffin JL, Atherton H, Shockcor J, Atzori L (2011) Metabolomics as a tool for cardiac research. Nat Rev Cardiol 8: 630-643.
10. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, et al (2012) Metabolic phenotyping in clinical and surgical environments. Nature 491: 384-392.
11. Bennett R (2005) The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 23: S154-162.
12. Folch J, Lees M, Sloan Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem 226: 497-509.
13. Gui C, Zhu W, Chen G, Luo X, Oi W. et al (2007) Understanding the Regulation Mechanisms of PAF Receptor by Agonists and Antagonists: Molecular Modeling and Molecular Dynamics Simulation Studies. PROTEINS: Structure, Function, and Bioinformatics 67: 41-52.
14. http://www.molecular-networks.com/online-demos/corina-demo.
15. Frisch MJ, Trucks GW; Schlegel HB; Scuseria GE; Robb MA, et al (2004) Gaussian 03, Revision C.02. Wallingford CT.
16. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174.
17. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
18. Kumar A, Hajjar E, Ruggerone P, Ceccarelli M (2010) Structural and dynamical properties of the porins OmpF and OmpC: insights from molecular simulations. J Phys Condens Matter 22: 454125.
19. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
20. Näim M, Bhat S, Rankin KN, Dennis S, Chowdhury SF, et al (2007) Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. J Chem Inf Model 47: 122-133.
21. Subbaiah PV, Chen SCH, Bagdade JD, Albers JJ (1985) Substrate Specificity of Plasma Lysolecithin Acyltransferase and the Molecular Species of Lecithin Formed by the Reaction. J Biol Chem 260: 5308-5314.
22. Karabina SA, Ninio E (2006) Plasma PAF-acetylhydrolase: An unfulfilled promise? Biochim Biophys Acta 1761: 1351-1358.
23. Fais A, Cacace E, Corda M, Era B, Peri M, et al (2013) Purine metabolites in fibromyalgia syndrome. Clin Biochem 46: 37-39.
24. Ishii I, Izumi T, Tsukamoto H, Umeyama H, Ui M, et al. (1997) Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J Biol Chem 272: 7846-7854.
25. Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, et al (1994) Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 68: 4628-4635.
26. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM (2000) Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69: 419-445.
27. Ishii S, Shimizu T (2000) Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice Prog Lipid Res 39: 41-82.
28. Demopoulos CA, Pinckard RN, Hanahan DJ (1979) Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators) J. Biol. Chem 254: 9355-9358.
29. Nakamura M, Honda ZI, Izumi T, Sakanaka C, Mutoh H, et al (1991) Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 266: 20400-20405.
30. Ye RD, Prossnitz ER, Zou A, Cochrane CG (1991) Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem Biophys Res Commun 180: 105-111.
31. Kunz D, Gerard NP, Gerard C (1992) The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. J Biol Chem 267: 9101-9106.
32. Tsoupras AB, Papakyriakou A, Constantinos A, Demopoulos CA, Philippopou-los AI (2013) Synthesis, biochemical evaluation and molecular modeling studies of novel rhodium complexes with nanomolar activity against Platelet Activating Factor. J Inorg Biochem 120: 63-73.
33. Tsuda M, Tozaki-saitoh H, Inoue K (2011) Platelet-Activating Factor and pain. Biol. Pharm. Bull 34: 1159-1162.
34. Morita K, Morioka N, Abdin J, Kitayama S, Nakata Y, et al (2004) Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice. Pain 111: 351-359.
35. Morita K, Kitayama T, Morioka N, Dohi T (2008) Glycinergic mediation of tactile allodynia induced by platelet-activating factor (PAF) through glutamate-NO-cyclic GMP signalling in spinal cord in mice. Pain 138: 525-536.
36. Dworkin RH, Fields HL (2005) Fibromyalgia from the perspective of neuropatic pain. J. Rheumatol 75(s): 1-5.
37. Hasegawa S, Kohro Y, Shiratori M, Ishii S, Shimizu T, et al (2010) Role of PAF Receptor in Proinflammatory Cytokine Expression in the Dorsal Root Ganglion and Tactile Allodynia in a Rodent Model of Neuropathic Pain. PLoS ONE 5: e10467.